Interestingly, CD48 has also been identified as a soluble form in human serum, and shown to be at increased levels in patients with arthritis, mild asthma, and advanced lymphoid malignancies, potentially acting as an antagonist or decoy receptor capable of blocking CD48:2B4 binding [44–46]. The gene discussed is CD48; the disease is arthritic joint disease.